Supernus Pharmaceuticals Valuation
| SUPN Stock | USD 36.10 0.12 0.33% |
At this time, the company appears to be undervalued. Supernus Pharmaceuticals has a current Real Value of $38.65 per share. The regular price of the company is $36.1. Our model measures the value of Supernus Pharmaceuticals from inspecting the company fundamentals such as Return On Equity of 0.0622, shares outstanding of 55.22 M, and Operating Margin of 0.16 % as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Supernus Pharmaceuticals' valuation include:
Price Book 1.9858 | Enterprise Value 1.6 B | Enterprise Value Ebitda 10.4993 | Price Sales 3.0677 | Forward PE 20.1613 |
Undervalued
Today
Please note that Supernus Pharmaceuticals' price fluctuation is very steady at this time. Calculation of the real value of Supernus Pharmaceuticals is based on 3 months time horizon. Increasing Supernus Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Supernus Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Supernus Stock. However, Supernus Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 36.1 | Real 38.65 | Target 42.25 | Hype 36.19 | Naive 35.49 |
The intrinsic value of Supernus Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Supernus Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Supernus Pharmaceuticals helps investors to forecast how Supernus stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Supernus Pharmaceuticals more accurately as focusing exclusively on Supernus Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Supernus Pharmaceuticals' intrinsic value based on its ongoing forecasts of Supernus Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Supernus Pharmaceuticals' closest peers.
Supernus Pharmaceuticals Cash |
|
Supernus Valuation Trend
Knowing Supernus Pharmaceuticals' actual value is paramount for traders when making sound investment determinations. Using both Supernus Pharmaceuticals' enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Supernus Revenue by Product
Supernus Pharmaceuticals Total Value Analysis
Supernus Pharmaceuticals is at this time projected to have valuation of 1.63 B with market capitalization of 2 B, debt of 41.53 M, and cash on hands of 360.79 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Supernus Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.63 B | 2 B | 41.53 M | 360.79 M |
Supernus Pharmaceuticals Investor Information
About 95.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.99. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Supernus Pharmaceuticals has Price/Earnings To Growth (PEG) ratio of 1.47. The entity had not issued any dividends in recent years. Based on the key indicators related to Supernus Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Supernus Pharmaceuticals may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter.Supernus Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Supernus Pharmaceuticals has an asset utilization ratio of 47.55 percent. This suggests that the Company is making $0.48 for each dollar of assets. An increasing asset utilization means that Supernus Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.Supernus Pharmaceuticals Ownership Allocation
The majority of Supernus Pharmaceuticals outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Supernus Pharmaceuticals to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Supernus Pharmaceuticals. Please pay attention to any change in the institutional holdings of Supernus Pharmaceuticals as this could imply that something significant has changed or is about to change at the company.Supernus Pharmaceuticals Profitability Analysis
The company reported the previous year's revenue of 607.52 M. Net Income was 1.32 M with profit before overhead, payroll, taxes, and interest of 580.02 M.About Supernus Pharmaceuticals Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Supernus Pharmaceuticals. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Supernus Pharmaceuticals based exclusively on its fundamental and basic technical indicators. By analyzing Supernus Pharmaceuticals's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Supernus Pharmaceuticals's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Supernus Pharmaceuticals. We calculate exposure to Supernus Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Supernus Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 523.7 M | 549.9 M | |
| Operating Profit Margin | (0.01) | (0.01) | |
| Gross Profit Margin | 0.86 | 0.82 |
Supernus Pharmaceuticals Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 55.5 M | |
| Quarterly Earnings Growth Y O Y | -0.992 | |
| Forward Price Earnings | 20.1613 |
Supernus Pharmaceuticals Current Valuation Indicators
Supernus Pharmaceuticals' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Supernus Pharmaceuticals' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Supernus Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Supernus Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Supernus Pharmaceuticals' worth.When determining whether Supernus Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Supernus Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Supernus Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Supernus Pharmaceuticals Stock: Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Supernus Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Supernus Pharmaceuticals. If investors know Supernus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Supernus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.99) | Earnings Share 1.07 | Revenue Per Share 11.877 | Quarterly Revenue Growth 0.142 | Return On Assets 0.0289 |
The market value of Supernus Pharmaceuticals is measured differently than its book value, which is the value of Supernus that is recorded on the company's balance sheet. Investors also form their own opinion of Supernus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Supernus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Supernus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Supernus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Supernus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Supernus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Supernus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.